Blood and Urine Metabolic Biomarkers Monitor Short-term Dietary Changes
|
By LabMedica International staff writers Posted on 04 Nov 2019 |

Image: Researchers have identified several chemical signatures, detectable in blood and urine, that can accurately measure dietary intake (Photo courtesy of Medical Xpress).
Metabolites found in plasma and urine samples may serve as responsive biomarkers reflecting short-term changes in the habitual diet.
Unhealthy eating patterns have been linked to the increase in obesity and related chronic diseases such as diabetes worldwide. However, existing methods of assessing dietary intake in nutritional epidemiology rely on food frequency questionnaires or dietary records that are prone to bias and selective reporting.
To improve this situation, investigators at McMaster University (Hamilton, ON, Canada) sought to identify metabolites in readily accessible blood or urine samples that would reflect short-term changes in dietary intake. Measurement of those markers would be used to compare the foods provided to study participants to what they reported they had eaten.
Over the course of this study, metabolic phenotyping was performed on 42 healthy participants from the Diet and Gene Intervention (DIGEST) pilot study, a parallel two-arm randomized clinical trial that provided complete diets to all participants. Matching single-spot urine and fasting plasma specimens were collected at baseline, and then following two weeks of either a Prudent or Western diet with a weight-maintaining menu plan designed by a dietician. The Prudent diet was rich in fruits, vegetables, lean meats, and whole grains. The Western diet was rich in trans fats, processed foods, red meat, and sweetened beverages. Targeted and nontargeted metabolite profiling was conducted for two weeks using three complementary analytical platforms.
A modest reduction in systolic and diastolic blood pressure, and total cholesterol was reported for participants following the Prudent diet after two weeks as compared to the Western diet; however, dietary adherence relied on participant self-reporting, and food preparation methods were not standardized.
Overall, 3-methylhistidine and proline betaine concentrations increased in both plasma and urine samples after participants were assigned a Prudent diet with a corresponding decrease in the Western diet group. Similarly, creatinine-normalized urinary imidazole propionate, hydroxypipecolic acid, dihydroxybenzoic acid, and enterolactone glucuronide, as well as plasma ketoleucine and ketovaline increased with a Prudent diet after adjustments for age, sex, and BMI. In contrast, plasma myristic acid, linoelaidic acid, linoleic acid, alpha-linoleic acid, pentadecanoic acid, alanine, proline, carnitine, and deoxycarnitine, as well as urinary acesulfame K increased among participants following a Western diet. Most metabolites were also correlated to changes in the average intake of specific nutrients from self-reported diet records reflecting good adherence to assigned food provisions.
"We were able to detect short-term changes in dietary patterns which could be measured objectively," said senior author Dr. Philip Britz-McKibbin, professor of chemistry and chemical biology at McMaster University. "And it did not take long for these significant changes to become apparent. This has been a major issue in nutritional research and may be one of the main reasons for the lack of real progress in nutritional sciences and chronic disease prevention."
The dietary biomarker study was published in the October 9, 2019, online edition of the journal Nutrients.
Related Links:
McMaster University
Unhealthy eating patterns have been linked to the increase in obesity and related chronic diseases such as diabetes worldwide. However, existing methods of assessing dietary intake in nutritional epidemiology rely on food frequency questionnaires or dietary records that are prone to bias and selective reporting.
To improve this situation, investigators at McMaster University (Hamilton, ON, Canada) sought to identify metabolites in readily accessible blood or urine samples that would reflect short-term changes in dietary intake. Measurement of those markers would be used to compare the foods provided to study participants to what they reported they had eaten.
Over the course of this study, metabolic phenotyping was performed on 42 healthy participants from the Diet and Gene Intervention (DIGEST) pilot study, a parallel two-arm randomized clinical trial that provided complete diets to all participants. Matching single-spot urine and fasting plasma specimens were collected at baseline, and then following two weeks of either a Prudent or Western diet with a weight-maintaining menu plan designed by a dietician. The Prudent diet was rich in fruits, vegetables, lean meats, and whole grains. The Western diet was rich in trans fats, processed foods, red meat, and sweetened beverages. Targeted and nontargeted metabolite profiling was conducted for two weeks using three complementary analytical platforms.
A modest reduction in systolic and diastolic blood pressure, and total cholesterol was reported for participants following the Prudent diet after two weeks as compared to the Western diet; however, dietary adherence relied on participant self-reporting, and food preparation methods were not standardized.
Overall, 3-methylhistidine and proline betaine concentrations increased in both plasma and urine samples after participants were assigned a Prudent diet with a corresponding decrease in the Western diet group. Similarly, creatinine-normalized urinary imidazole propionate, hydroxypipecolic acid, dihydroxybenzoic acid, and enterolactone glucuronide, as well as plasma ketoleucine and ketovaline increased with a Prudent diet after adjustments for age, sex, and BMI. In contrast, plasma myristic acid, linoelaidic acid, linoleic acid, alpha-linoleic acid, pentadecanoic acid, alanine, proline, carnitine, and deoxycarnitine, as well as urinary acesulfame K increased among participants following a Western diet. Most metabolites were also correlated to changes in the average intake of specific nutrients from self-reported diet records reflecting good adherence to assigned food provisions.
"We were able to detect short-term changes in dietary patterns which could be measured objectively," said senior author Dr. Philip Britz-McKibbin, professor of chemistry and chemical biology at McMaster University. "And it did not take long for these significant changes to become apparent. This has been a major issue in nutritional research and may be one of the main reasons for the lack of real progress in nutritional sciences and chronic disease prevention."
The dietary biomarker study was published in the October 9, 2019, online edition of the journal Nutrients.
Related Links:
McMaster University
Latest Molecular Diagnostics News
- Blood Test Could Spot Common Post-Surgery Condition Early
- New Blood Test Can Help Predict Testicular Cancer Recurrence
- New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
- New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
- Cell-Free DNA Predicts Bloodstream Infections in Children with Leukemia
- Study Uses Blood Samples to Identify Diseases Years Before They Start
- MicroRNA-Based Method Predicts CKD and Cardiovascular Risk
- Swab Test Helps Transplant Patients Receive Right Anti-Rejection Medication Dose
- Blood Test Predicts Which Bladder Cancer Patients May Safely Skip Surgery
- Ultra-Sensitive DNA Test Identifies Relapse Risk in Aggressive Leukemia
- Blood Test Could Help Detect Gallbladder Cancer Earlier
- New Blood Test Score Detects Hidden Alcohol-Related Liver Disease
- New Blood Test Predicts Who Will Most Likely Live Longer
- Genetic Test Predicts Radiation Therapy Risk for Prostate Cancer Patients
- Genetic Test Aids Early Detection and Improved Treatment for Cancers
- New Genome Sequencing Technique Measures Epstein-Barr Virus in Blood
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
World’s First Optical Microneedle Device to Enable Blood-Sampling-Free Clinical Testing
Blood sampling is one of the most common clinical procedures, but it can be difficult or uncomfortable for many patients, especially older adults or individuals with certain medical conditions.... Read more
Pathogen-Agnostic Testing Reveals Hidden Respiratory Threats in Negative Samples
Polymerase Chain Reaction (PCR) testing became widely recognized during the COVID-19 pandemic as a powerful method for detecting viruses such as SARS-CoV-2. PCR belongs to a group of diagnostic methods... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







